Observational findings reveal tofacitinib reduces myocardial inflammation in cardiac sarcoidosis, suggesting a steroid-sparing approach.
Tofacitinib shows promising results in managing treatment-refractory CS, with seven out of eight patients achieving significant reduction in myocardial inflammation and corticosteroid dependency. However, further studies with larger prospective cohorts are essential to solidify these findings and assess the drug's efficacy and safety profile in this complex patient group.
No takes yet. Share an insight, caveat, or question.
Frischknecht et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: